{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immune+Globulin+Intravenous+%28human%29%2C+10%25", "query": { "intervention": "Immune Globulin Intravenous (human), 10%" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 145, "total_pages": 15, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immune+Globulin+Intravenous+%28human%29%2C+10%25&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-09T19:07:29.872Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06084481", "title": "Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatocellular Carcinoma", "Pancreatic Ductal Adenocarcinoma", "Biliary Tract Cancers", "Esophageal Squamous Cell Carcinoma", "Triple Negative Breast Cancer", "Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer", "Head and Neck Squamous-Cell Carcinoma", "Platinum Resistant High Grade Epithelial Ovarian Cancer" ], "interventions": [ { "name": "ABBV-400", "type": "DRUG" }, { "name": "Itraconazole (ITZ)", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 325, "start_date": "2023-11-09", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-09T19:07:29.872Z", "location_count": 20, "location_summary": "Duarte, California • San Francisco, California • Aurora, Colorado + 15 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06084481" }, { "nct_id": "NCT00220740", "title": "Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Polyradiculoneuropathy, Chronic Inflammatory Demyelinating" ], "interventions": [ { "name": "Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified", "type": "DRUG" }, { "name": "Albumin (Human) 25%, United States Pharmacopeia (USP)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Grifols Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 117, "start_date": "2004-04", "completion_date": "2006-06", "has_results": true, "last_update_posted_date": "2016-03-23", "last_synced_at": "2026-10-09T19:07:29.872Z", "location_count": 6, "location_summary": "New Haven, Connecticut • St Louis, Missouri • New York, New York + 3 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00220740" }, { "nct_id": "NCT04083183", "title": "Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Malignant Neoplasm" ], "interventions": [ { "name": "Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Lapine T-Lymphocyte Immune Globulin", "type": "BIOLOGICAL" }, { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Hematopoietic Cell Transplantation", "type": "PROCEDURE" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 40, "start_date": "2020-06-16", "completion_date": "2028-01-09", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-09T19:07:29.872Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04083183" }, { "nct_id": "NCT00246012", "title": "A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Intetumumab", "type": "DRUG" }, { "name": "Dacarbazine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Centocor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 144, "start_date": "2005-05", "completion_date": "2009-02", "has_results": true, "last_update_posted_date": "2013-08-19", "last_synced_at": "2026-10-09T19:07:29.872Z", "location_count": 17, "location_summary": "Scottsdale, Arizona • La Jolla, California • Santa Monica, California + 14 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00246012" }, { "nct_id": "NCT06444048", "title": "Phase 1, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of an Enterovirus D68-specific Monoclonal Antibody in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Enterovirus Infection" ], "interventions": [ { "name": "EV68-228-N", "type": "BIOLOGICAL" }, { "name": "Placebo for EV68-228-N", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 36, "start_date": "2024-06-26", "completion_date": "2025-04-11", "has_results": true, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-10-09T19:07:29.872Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Nashville, Tennessee", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06444048" }, { "nct_id": "NCT00630552", "title": "QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adenocarcinoma of the Pancreas", "Metastatic Pancreatic Cancer", "Pancreatic Cancer" ], "interventions": [ { "name": "Placebo", "type": "OTHER" }, { "name": "AMG 479", "type": "DRUG" }, { "name": "AMG 655", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "NantCell, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 138, "start_date": "2007-06", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2024-10-17", "last_synced_at": "2026-10-09T19:07:29.872Z", "location_count": 44, "location_summary": "Alhambra, California • Bakersfield, California • Fullerton, California + 37 more", "locations": [ { "city": "Alhambra", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00630552" }, { "nct_id": "NCT05005403", "title": "Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer", "Head and Neck Squamous Cell Carcinoma", "Micro Satellite Stable Colorectal Cancer", "Gastric/Esophageal Cancer", "High-Grade Serous Ovarian Cancer", "Pancreatic Cancer", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "Azirkitug", "type": "DRUG" }, { "name": "Budigalimab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Telisotuzumab Adizutecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 694, "start_date": "2021-11-01", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-10-09T19:07:29.872Z", "location_count": 20, "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 15 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05005403" }, { "nct_id": "NCT00176865", "title": "Stem Cell Transplant for Immunologic or Histiocytic Disorders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hemophagocytic Lymphohistiocytosis", "X-Linked Lymphoproliferative Disorders", "Chediak-Higashi Syndrome", "Griscelli Syndrome", "Immunologic Deficiency Syndromes", "Langerhans-Cell Histiocytosis" ], "interventions": [ { "name": "Stem Cell Transplant", "type": "PROCEDURE" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Anti-thymocyte globulin (ATG)", "type": "DRUG" }, { "name": "Campath 1H", "type": "DRUG" }, { "name": "Cyclosporin A", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "Intravenous immunoglobulin (IVIG)", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "35 Years", "sex": "ALL", "summary": "Up to 35 Years" }, "enrollment_count": 19, "start_date": "2002-08", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2017-12-28", "last_synced_at": "2026-10-09T19:07:29.872Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00176865" }, { "nct_id": "NCT04471038", "title": "Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Influenza Type A", "Influenza Type B", "Influenza" ], "interventions": [ { "name": "SAB-176", "type": "BIOLOGICAL" }, { "name": "Normal Saline", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "SAb Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 27, "start_date": "2020-07-29", "completion_date": "2021-04-19", "has_results": true, "last_update_posted_date": "2025-01-06", "last_synced_at": "2026-10-09T19:07:29.872Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04471038" }, { "nct_id": "NCT02915263", "title": "The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Complications", "Diabetes Mellitus", "Diabetic Neuropathies" ], "interventions": [ { "name": "IGIV-C", "type": "DRUG" }, { "name": "0.9% Sodium Chloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 13, "start_date": "2017-09-11", "completion_date": "2022-02-01", "has_results": true, "last_update_posted_date": "2024-05-07", "last_synced_at": "2026-10-09T19:07:29.872Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02915263" } ] }